Assembly and morphology of HIV: potential effect of structure on viral function. The neutralizing antibody response to HIV viral evasion and escape from humoral immunity. Inhibition of infectious human immunodeficiency virus type 1 particle formation by Gag protein-derived peptides.
J Gen Virol. M48U1 CD4 mimetic has a sustained inhibitory effect on cell-associated HIV-1 by attenuating virion infectivity through gp shedding.
Virus-host interactions in HIV pathogenesis: directions for therapy. Adv Dent Res. The NF-kappa B binding sites in the human immunodeficiency virus type 1 long terminal repeat are not required for virus infectivity. Virus Res. Locatelli S, Peeters M. Cross-species transmission of simian retroviruses: how and why they could lead to the emergence of new diseases in the human population. Characterization of a novel simian immunodeficiency virus from guereza colobus monkeys Colobus guereza in Cameroon: a new lineage in the nonhuman primate lentivirus family.
Variability of human immunodeficiency virus type 2 HIV-2 infecting patients living in France. Update on the human immunodeficiency virus. Med Mal Infect Paris ; 43 — J Clin Virol.
Eradicating HIV infection: seeking to clear a persistent pathogen. Nat Rev Microbiol. Crystal structure of bacteriophage T7 RNA polymerase at 3. Cell Res. Moudgil T, Daar ES. Infectious decay of human immunodeficiency virus type 1 in plasma. J Infect Dis. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time.
Distinct mechanisms trigger apoptosis in human immunodeficiency virus type 1-infected and in uninfected bystander T lymphocytes. Induction of apoptosis by primary HIV-1 isolates correlates with productive infection in peripheral blood mononuclear cells. J Clin Invest. Virus safety of avital bone tissue transplants: evaluation of sterilization steps of spongiosa cuboids using a peracetic acid-methanol mixture.
Inactivation of lymphadenopathy-associated virus by heat, gamma rays, and ultraviolet light. Effect of gamma irradiation on human cortical bone transplants contaminated with enveloped and non-enveloped viruses. A novel approach to pathogen reduction in platelet concentrates using short-wave ultraviolet light.
Dry-heat treatment process for enhancing viral safety of an antihemophilic factor VIII concentrate prepared from human plasma.
J Microbiol Biotechnol. PLOS One. J Immunol. The HIV-1 env protein: a coat of many colors. HIV binding, penetration, and primary infection in human cervicovaginal tissue. Analysis of HIV-1 load in blood, semen and saliva: evidence for different viral compartments in a cross-sectional and longitudinal study. Compartmentalization of HIV-1 according to antiretroviral therapy: viral loads are correlated in blood and semen but poorly in blood and saliva. An effective and safe protocol involving zidovudine and caesarean section to reduce vertical transmission of HIV-1 infection.
Interventions to reduce mother-to-child transmission of HIV infection: new developments and current controversies. Comparison of human immunodeficiency virus assays in window phase and elite controller samples: viral load distribution and implications for transmission risk. Cockerham LR, Hatano H. Elite control of HIV: is this the right model for a functional cure? Trends Microbiol. Dynamics of cell-free viral burden in HIVinfected patients.
Effect of antiretroviral therapy on HIV reservoirs in elite controllers. Kong L, Sattentau QJ. Antigenicity and immunogenicity in HIV-1 antibody-based vaccine design. Factors affecting survival in patients with the acquired immunodeficiency syndrome. BMC Public Health.
Prevalence and prognostic value. J Hepatol. Management of chronic hepatitis C in HIV-infected patients. The cancer-associated virus landscape in HIV patients with oral hairy leukoplakia, Kaposi's sarcoma, and Non-Hodgkin lymphoma. Tracking a century of global expansion and evolution of HIV to drive understanding and to combat disease. Lancet Infect Dis. Tracing the origin and history of the HIV-2 epidemic. Human immunodeficiency virus type 1 epidemic: date of origin, population history, and characterization of early strains.
Epidemiol Bull. Robert Koch-Institut. Berlin: Robert Koch-Institut; Infect Genet Evol. Burruano L, Kruglov Y. Gend Med. Piot P, Quinn TC. Response to the AIDS pandemic - a global health model. N Engl J Med. Effect of sex steroid hormones on replication and transmission of major HIV subtypes. J Steroid Biochem Mol Biol.
Towards a better understanding of the epidemiology of HIV Clade C HIV-1 isolates circulating in Southern Africa exhibit a greater frequency of dicysteine motif-containing Tat variants than those in Southeast Asia and cause increased neurovirulence.
Genome Announc. The Kirby Institute. Persistence of attenuated HIV-1 rev alleles in an epidemiologically linked cohort of long-term survivors infected with nef-deleted virus.
Reduction of the diagnostic window with a new combined p24 antigen and human immunodeficiency virus antibody screening assay. J Virol Methods. New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes.
Failure of a novel, rapid antigen and antibody combination test to detect antigen-positive HIV infection in African adults with early HIV infection. Contribution of immunological and virological factors to extremely severe primary HIV type 1 infection. Clin Infect Dis. DVV e. GfV e. Bundesgesundhbl Gesundheitsforsch Gesundheitsschutz. Blut AK. Heaviness of HIV particles in quantum relation to viral infectiousness and responsiveness to interferon. In: Andrieu JM, editor.
Paris: John Libbey Eurotext; Performance evaluation of a new fourth-generation HIV combination antigen-antibody assay. Med Microbiol Immunol.
Early detection of antibodies to HIV-1 by third-generation assays. Votum 2. Human immunodeficiency virus transfusion transmission despite nucleic acid testing. International survey on NAT testing of blood donations: expanding implementation and yield from to Vox Sang. An international collaborative study to establish the 1st international standard for HIV-1 RNA for use in nucleic acid-based techniques.
An international collaborative study to establish a replacement World Health Organization International Standard for human immunodeficiency virus 1 RNA nucleic acid assays. J Clin Microbiol. Detection of phylogenetically diverse human immunodeficiency virus type 1 groups M and O from plasma by using highly sensitive and specific generic primers. Molecular assays for monitoring HIV infection and antiretroviral therapy.
Expert Rev Mol Diagn. Blood screening nucleic acid amplification tests for human immunodeficiency virus type 1 may require two different amplification targets.
Risk minimization measures for blood screening HIV-1 nucleic acid amplification technique assays in Germany. How safe is safe: new human immunodeficiency virus type 1 variants missed by nucleic acid testing. Experience of German Red Cross blood donor services with nucleic acid testing: results of screening more than 30 million blood donations for human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus.
Morel P. Ten years of nucleic acid testing: lessons and prospects. Transfus Clin Biol. Validation and clinical use of a sensitive HIV-2 viral load assay that uses a whole virus internal control. Woche Robert Koch Institute. HIV-Infektion; pp. Prevalence of human immunodeficiency virus RNA and antibody in first-time, lapsed, and repeat blood donations across five international regions and relative efficacy of alternative screening scenarios.
Juli Sexual risk behaviour and donor deferral in Europe. Bundesanzeiger 16 May , ; 90 — Experience of mandatory nucleic acid test NAT screening across all blood organizations in Germany: NAT yield versus breakthrough transmissions. Infectivity of human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus and risk of transmission by transfusion.
Refinement of a viral transmission risk model for blood donations in seroconversion window phase screened by nucleic acid testing in different pool sizes and repeat test algorithms. Transmission networks of HIV-1 among men having sex with men in the Netherlands.
Votum Seroreversion in vertically HIVinfected children treated early and efficiently: rule or exception? Recommendation for a Public health Approach, Revision. Geneva: World Health Organization; Berlin: Springer; First transmission of human immunodeficiency virus type 1 by a cellular blood product after mandatory nucleic acid screening in Germany.
Phenotypic properties of transmitted founder HIV Genetic variants and susceptibility to neurological complications following West Nile virus infection. Effect of age at seroconversion on the natural AIDS incubation distribution.
Immune control of HIV-1 after early treatment of acute infection. Aberg JA. Aging, inflammation, and HIV infection. Top Antivir Med. A global approach to HIV-1 vaccine development. Immunol Rev. Progress in HIV-1 vaccine development. J Allergy Clin Immunol. Broder S. Twenty-five years of translational medicine in antiretroviral therapy: promises to keep.
Sci Transl Med. Bull World Health Organ. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor T monotherapy.
Antimicrob Agents Chemother. HIV-1 reverse transcriptase still remains a new drug target: structure, function, classical inhibitors, and new inhibitors with innovative mechanisms of action. Mol Biol Int. Trends of prevalence of primary HIV drug resistance in Germany. J Antimicrob Chemother. Molecular basis of human immunodeficiency virus type 1 drug resistance: overview and recent developments. Autoimmune Diseases. Disease-Specific Research. Characterizing Disease. Researcher Resources.
Dengue Fever. Shiga Toxin-Producing E. Researching Ebola in Africa. Photo Essay. Food Allergy. Research Approach. Treatment for Living with Food Allergy. Fungal Diseases. Group A Streptococcal Infections. Vaccine Research. Types of Group A Strep. Vaccine Development.
Basic Research. Leprosy Hansen's Disease. Lyme Disease. Antibiotic Treatment. Chronic Lyme Disease. Featured Research. Types of PIDDs. Talking to Your Doctor. Therapeutic Approaches. Animal Prion Diseases and Humans. Rocky Mountain Spotted Fever. Schistosomiasis Bilharzia. Tickborne Diseases. Tuberculosis Drugs. But HIV medicine can slow or prevent progression of the disease.
With the advancements in treatment, progression to Stage 3 is less common today than in the early days of HIV. Skip directly to site content Skip directly to page options Skip directly to A-Z link. Section Navigation. Facebook Twitter LinkedIn Syndicate. About HIV. Minus Related Pages. If you take HIV medicine every day, exactly as prescribed and get and keep an undetectable viral load, you can protect your health and have effectively no risk of transmitting HIV to your sexual partner s.
But if your viral load is detectable, you can transmit HIV during this stage, even when you have no symptoms. This is the late stage of HIV infection. Each of these symptoms can also be related to other illnesses. See your health care provider if you are experiencing any of these symptoms.
Content Source: HIV. Many Federal agencies have developed public awareness and education campaigns to address HIV prevention, treatment, care, and research. Also included is information about campaigns related to the prevention and diagnosis of hepatitis B and C. El VIH es una amenaza de salud grave para las comunidades latinas, quienes se encuentran en gran desventaja respecto de la incidencia de esta enfermedad en los Estados Unidos.
Want to stay abreast of changes in prevention, care, treatment or research or other public health arenas that affect our collective response to the HIV epidemic? Or are you new to this field?
0コメント